Cargando…
Corrigendum to “HIV remission trial investigators’ attitudes towards risk and risk mitigation in trials that include treatment interruption” [J Virus Erad 9 (2) (June 2023) 100331]
Autores principales: | Okumu, Eunice Akinyi, Henderson, Gail E., Golin, Carol, Kuczynski, Kriste, Ormsby, Nuchanart Q., Peay, Holly L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407945/ https://www.ncbi.nlm.nih.gov/pubmed/37560051 http://dx.doi.org/10.1016/j.jve.2023.100340 |
Ejemplares similares
-
HIV remission trial investigators’ attitudes towards risk and risk mitigation in trials that include treatment interruption
por: Okumu, Eunice Akinyi, et al.
Publicado: (2023) -
Recommendations from Thai stakeholders about protecting HIV remission (‘cure’) trial participants: report from a participatory workshop
por: Peay, Holly L, et al.
Publicado: (2020) -
Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment
por: Henderson, Gail E, et al.
Publicado: (2018) -
Corrigendum to ‘Decision making for invasive and non-invasive optional procedures within an acute HIV research cohort in Bangkok,’ [Contemporary Clinical Trials Communication (2023)101054]
por: Isaacson, Sinéad, et al.
Publicado: (2023) -
Progress Toward Poliomyelitis Eradication — Pakistan, January 2022–June 2023
por: Mbaeyi, Chukwuma, et al.
Publicado: (2023)